Quality of Life of Oligometastatic and Polymetastatic Head and Neck Squamous Cell Carcinoma Patients
The Laryngoscope · 2024-07 · 134 (7) · 3170-3176
DOI: 10.1002/lary.31325 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 07.02.2024. Verfasst von Diako Berzenji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Quality of Life, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Evidence suggests that distant metastasis in head and neck squamous cell carcinoma is a spectrum of disease. Previous studies show that oligometastasis has favorable survival compared with polymetastasis. The quality of life of patients with oligometastasis remains unknown. To further solidify the position of oligometastasis as a separate entity, we hypothesized that oligometastatic patients experience better quality of life than polymetastatic patients.
Methods
Patients with distant metastasis were stratified into three groups: oligometastasis (≤3 metastatic foci in ≤2 anatomic sites), explosive metastasis (≥4 metastatic foci at one anatomic site), and explosive‐disseminating metastasis (spread to ≥3 anatomic sites). Quality of life was assessed every 2 months post distant metastasis diagnosis.
Results
Between January 1, 2016, and December 31, 2021, a total of 161 patients with distant metastasis were identified, with a total of 397 measurements. In this group, 57 (35.4%) patients had oligometastasis, 35 (21.7%) patients had explosive metastasis, and 69 (42.9%) patients had explosive‐disseminating metastasis. Their median post‐distant metastasis survivals were 8.5 months, 3.2 months, and 3.2 months respectively ( p < 0.001). A significantly better overall quality of life was observed in the oligometastasis group compared with the polymetastatic groups (+0.75 out of 7, p < 0.05). Furthermore, oligometastatic patients performed better in the subdomains of “physical functioning,” “fatigue,” and “pain.” Conclusion Results from this study underscore that subgroups exist regarding quality of life and survival within distant metastasis, with polymetastatic patients performing worse than oligometastatic patients. This highlights the significance of tailored interventions that consider the unique challenges faced by each metastatic group of patients. Level of Evidence 3, retrospective cohort study Laryngoscope , 134:3170–3176, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Oral and Maxillofacial Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ORCID-Profile: Diako Berzenji, Maarten C Dorr
Zitieren
APA
Berzenji, D., Dorr, M. C., Sewnaik, A., Mast, H., Offerman, M. P. J., Baatenburg de Jong, R. J., & Hardillo, J. A. (2024). Quality of Life of Oligometastatic and Polymetastatic Head and Neck Squamous Cell Carcinoma Patients. The Laryngoscope, 134(7), 3170-3176. https://doi.org/10.1002/lary.31325
Vancouver
Berzenji D, Dorr MC, Sewnaik A, Mast H, Offerman MPJ, Baatenburg de Jong RJ, et al. Quality of Life of Oligometastatic and Polymetastatic Head and Neck Squamous Cell Carcinoma Patients. The Laryngoscope. 2024;134(7):3170-3176. doi:10.1002/lary.31325
BibTeX
@article{Berzenji2024,
author = {Berzenji, Diako and Dorr, Maarten C and Sewnaik, Aniel and Mast, Hetty and Offerman, Marinella P J and Baatenburg de Jong, Robert J and Hardillo, Jose A},
title = {Quality of Life of Oligometastatic and Polymetastatic Head and Neck Squamous Cell Carcinoma Patients},
journal = {The Laryngoscope},
year = {2024},
volume = {134},
number = {7},
pages = {3170--3176},
doi = {10.1002/lary.31325}
}
EUVIMED